Article by Julia Kollewe The Guardian, Tuesday 27 November 2012 18.14 GMT … Biovista is in the process of filing for novel use patents for 12 drugs with potential in Parkinson’s, Alzheimer’s, epilepsy, depression and sleep disorders. …
News
World Drug Repositioning Congress
Join us at the upcoming World Drug Repositioning Congress, 4 – 5 December 2012, 20 F Street NW Conference Center, Washington, DC, US Biovista’s Aris Persidis is presenting a talk titled Very large scale systematic drug repositioning as a business and technology driver Topics covered include: Big data technologies enabling the deployment of systemic drug … Read More
Partnering for Cures meeting
Join us at the upcoming Partnering for Cures meeting, November 28-30, 2012 in NY City. Biovista will be co-presenting with the CFIDS Association of America its repositioning work on Chronic Fatigue Syndrome within the event’s prestigious Innovator Presentations session. The session focuses on organizations “engaged in innovative, cross-sector collaborations aimed at reducing the time … Read More
SciBX interviews Biovista’s CMO on Remyelination
Lauren Martz of Nature’s Science Business Exchange (SciBX) interviews Biovista’s Dr Deftereos on “Myelination from neural stem cells”. Read article here.
The Path of Least Resistance: Repositioned Drugs Surpass New Brands
Article by PharmExec’s Clark Herman on the 505(b)(2) pathway for drug approval … Aris Persidis, president and co-founder of Biovista, a company focused on the 505(b)(2), adds, “In addition, the first to file patent regulations that will take effect in the US next year are making companies realize that they may be susceptible to competitors … Read More